Aug. 3 (UPI) -- U.S. pharma company Eli Lilly said Monday it has begun a large-scale clinical trial for a COVID-19 antiviral drug for elderly persons living in nursing homes and similar settings.
The company said a third-stage trial of its experimental LY-CoV555 monoclonal antibody treatment began at several long-term U.S. care facilities and is expected to enroll as many as 2,400 participants.